Fulvestrant Superior to Anastrozole for HR-positive Advanced Breast Cancer

Share this content:
Among patients with previously untreated breast cancer, endocrine therapy with fulvestrant significantly prolonged progression-free survival.
Among patients with previously untreated breast cancer, endocrine therapy with fulvestrant significantly prolonged progression-free survival.

Among patients with previously untreated hormone receptor (HR)-positive, locally-advanced or metastatic breast cancer, endocrine therapy with fulvestrant significantly prolonged progression-free survival compared with anastrozole, according to a study published in The Lancet.1

Aromatase inhibitors are a standard of care for women with HR-positive, locally advanced or metastatic breast cancer, though it is unclear whether 1 treatment option is superior to another.

Researchers investigated whether fulvestrant, a selective estrogen receptor degrader, could improve progression-free survival compared with anastrozole, a third-generation aromatase inhibitor, among postmenopausal patients who had not received prior endocrine therapy.

For the international, double-blind, phase 3 FALCON study (ClinicalTrials.gov Identifier: NCT01602380), researchers enrolled 462 patients with histologically confirmed estrogen receptor-positive or progesterone receptor-positive, or both, locally advanced or metastatic breast cancer. Participants were randomly assigned 1:1 to receive fulvestrant intramuscular injections or oral anastrozole.

Treatment with fulvestrant significantly reduced the risk of progression or death by nearly 20% compared with anastrozole (hazard ratio, 0.797; 95% CI, 0.637-0.999; P = .0486).

Median progression-free survival was 16.6 months (95% CI, 13.83-20.99) in the fulvestrant arm vs 13.8 months (95% CI, 11.99-16.56) in the anastrozole arm.

The most common adverse events were arthralgia and hot flushes. Seven percent of patients in the fulvestrant group discontinued treatment due to adverse events compared with 5% of those treated with anastrozole.

RELATED: Prevention of Ventricular Remodeling in HER2-positive Breast Cancer Treated With Trastuzumab

The findings support the use of fulvestrant as a standard of care for first-line treatment of postmenopausal women with HR-positive advanced breast cancer who have not received previous endocrine therapy.

Reference

  1. Robertson JF, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016 Nov 28. doi: 10.1016/S0140-6736(16)32389-3 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters